TMCnet News
Seattle Genetics Highlights Broad Presence at the American Association for Cancer Research (AACR) Annual MeetingSeattle Genetics, Inc. (Nasdaq: SGEN) today highlighted the company's broad presence at the upcoming 106th Annual Meeting of the American Association for Cancer Research (AACR) being held April 18 to 22, 2015 in Philadelphia, PA, including eight abstracts on antibody-drug conjugate (ADC (News - Alert)) technology and first preclinical data from a new immuno-oncology antibody utilizing sugar-engineered antibody (SEA) technology. Preclinical abstracts accepted for presentation include data in support of SGN (News - Alert)-CD19A and SGN-CD70A, and activation of immune cells by SEA-CD40 and ADCETRIS (brentuximab vedotin). In addition, multiple presentations will be featured in Special Sessions and Symposia by Seattle Genetics' leadership team on the critical role of ADCs in the current and future cancer treatment landscape. Finally, SGN-CD33A will be featured in the "New Drugs on the Horizon" session, focusing on the preclinical rationale and early clinical data for this first-in-class ADC incorporating Seattle Genetics' newest pyrrolobenzodiazepine (PBD) dimer technology. "Seattle Genetics has an impressive collection of new data at AACR, demonstrating continued leadership in the field of ADC therapeutics. Abstracts and presentations cover five clinical-stage programs, demonstrating novel preclinical combination regimens, mechanisms of action and advances in ADC technology," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. "We are also now building on our expertise in empowered antibodies by initiating phase 1 clinical development of SEA-CD40, a novel CD40-directed immuno-oncology agent. Finally, we will present data on immunogenic cell death caused by ADCETRIS in vitro, providing further rationale for two planned clinical trials in combination with nivolumab under our recently announced collaboration with Bristol Myers Squibb." ADCs are monoclonal antibodies designed to selectively deliver cytotoxic agents to tumor cells. With over seventeen years of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents and stable linker systems that attach these cytotoxic agents to the antibody. Seattle Genetics' linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. Seattle Genetics is developing a novel approach called SEA technology which is designed to increase the potency of monoclonal antibodies. SEA technology produces a non-fucosylated monoclonal antibody, resulting in an enhanced innate immune response. SEA-CD40 represents the first clinical antibody employing SEA technology. Enhanced binding to effector cells results in better crosslinking and activation of CD40 signaling in immune cells. This stimulation of the patient's own immune cells has the potential to result in antitumor activity. Multiple corporate and executive presentations are being featured at AACR. Abstracts can be found at www.aacr.org and include the following: Advances with ADC Pipeline, Research Programs and Technology Six presentations will highlight advances with Seattle Genetics proprietary ADC pipeline programs, research programs and technology, including:
Immuno-Oncology Presentations
Senior Management Presentations AACR selected members of Seattle Genetics' leadership team to present in several sessions on the integral role of ADCs in targeted therapy, including:
About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS® (brentuximab vedotin) is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 50 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com. Forward Looking Statement Certain of the statements made in this press release are forward looking, such as those, among others, relating to future development activities including clinical trials and the therapeutic potential of ADCETRIS and our product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include lack of efficacy or risk of adverse events as these product candidates advance in development. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company's Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
|